Literature DB >> 3530846

Identification of glucokinase as an alloxan-sensitive glucose sensor of the pancreatic beta-cell.

M D Meglasson, P T Burch, D K Berner, H Najafi, F M Matschinsky.   

Abstract

Alloxan inactivated glucokinase in intact, isolated pancreatic islets incubated in vitro. Inactivation of glucokinase was antagonized by 30 mM glucose present during incubation of islets with alloxan. Glucokinase partially purified from transplantable insulinomas or rat liver was inactivated by alloxan with a half-maximal effect at 2-4 microM alloxan. Inactivation of purified glucokinase was antagonized by glucose, mannose, and 2-deoxyglucose in order of decreasing potency but not by 3-O-methylglucose. Glucose anomers at 6 and 14 mM were discriminated as protecting agents, with the alpha-anomer more effective than the beta-anomer. Glucokinase was not protected from alloxan inactivation by N-acetylglucosamine, indicating that the reactive site for alloxan is not the active site; therefore, glucose may protect glucokinase by inducing a conformational change. Glucokinase is thought to be the glucose sensor of the pancreatic beta-cell. The finding that glucokinase is inactivated by alloxan and protected by glucose with discrimination of its anomers similar to inhibition of glucose-stimulated insulin secretion by alloxan supports this hypothesis and appears to explain the mechanism for inhibition of hexose-stimulated insulin secretion by this agent and the unique role of glucose and mannose as protecting agents.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3530846     DOI: 10.2337/diab.35.10.1163

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  16 in total

Review 1.  Chemical approaches to understanding O-GlcNAc glycosylation in the brain.

Authors:  Jessica E Rexach; Peter M Clark; Linda C Hsieh-Wilson
Journal:  Nat Chem Biol       Date:  2008-02       Impact factor: 15.040

Review 2.  The chemical neurobiology of carbohydrates.

Authors:  Heather E Murrey; Linda C Hsieh-Wilson
Journal:  Chem Rev       Date:  2008-05-02       Impact factor: 60.622

Review 3.  [Insulin producing cells as therapy in diabetes mellitus].

Authors:  W J Schnedl; H E Hohmeier; C B Newgard
Journal:  Naturwissenschaften       Date:  1996-01

Review 4.  Alloxan: history and mechanism of action.

Authors:  S Lenzen; U Panten
Journal:  Diabetologia       Date:  1988-06       Impact factor: 10.122

5.  Regulation of insulin secretion and beta-cell mass by activating signal cointegrator 2.

Authors:  Seon-Yong Yeom; Geun Hyang Kim; Chan Hee Kim; Heun Don Jung; So-Yeon Kim; Joong-Yeol Park; Youngmi Kim Pak; Dong-Kwon Rhee; Shao-Qing Kuang; Jianming Xu; Duck Jong Han; Dae-Kyu Song; Jae Woon Lee; Ki-Up Lee; Seung-Whan Kim
Journal:  Mol Cell Biol       Date:  2006-06       Impact factor: 4.272

6.  B cell insensitivity in a rat model of non-insulin-dependent diabetes. Evidence for a rapidly reversible effect of previous hyperglycemia.

Authors:  V Grill; M Westberg; C G Ostenson
Journal:  J Clin Invest       Date:  1987-09       Impact factor: 14.808

7.  ATP-dependent sugar transport complexity in human erythrocytes.

Authors:  Jeffry M Leitch; Anthony Carruthers
Journal:  Am J Physiol Cell Physiol       Date:  2006-08-23       Impact factor: 4.249

8.  O-GlcNAcylation: a novel post-translational mechanism to alter vascular cellular signaling in health and disease: focus on hypertension.

Authors:  Victor V Lima; Christiné S Rigsby; David M Hardy; R Clinton Webb; Rita C Tostes
Journal:  J Am Soc Hypertens       Date:  2009 Nov-Dec

9.  The diabetogenic agent alloxan increases K+ permeability by a mechanism involving activation of ATP-sensitive K(+)-channels in mouse pancreatic beta-cells.

Authors:  P B Carroll; A S Moura; E Rojas; I Atwater
Journal:  Mol Cell Biochem       Date:  1994-11-23       Impact factor: 3.396

10.  Structural requirements of alloxan and ninhydrin for glucokinase inhibition and of glucose for protection against inhibition.

Authors:  S Lenzen; F H Brand; U Panten
Journal:  Br J Pharmacol       Date:  1988-11       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.